Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
Viridian Therapeutics, Inc. (VRDN) had Pre-Tax Income of $-104.90M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.14M |
|
$-104.90M |
|
-- |
|
$0.14M |
|
$116.31M |
|
$-116.17M |
|
$11.27M |
|
|
Pre-Tax Income |
$-104.90M |
$-104.90M |
|
$-104.90M |
|
$-104.90M |
|
$-104.90M |
|
$-104.90M |
|
$-116.17M |
|
$-117.91M |
|
102.21M |
|
102.21M |
|
$-0.90 |
|
$-0.90 |
|
| Balance Sheet Financials | |
$784.74M |
|
$1.13M |
|
$4.27M |
|
$789.02M |
|
$51.80M |
|
$50.44M |
|
$101.20M |
|
$153.01M |
|
$503.95M |
|
$636.01M |
|
$636.01M |
|
102.46M |
|
| Cash Flow Statement Financials | |
$-119.65M |
|
$77.26M |
|
$6.36M |
|
$212.38M |
|
$176.35M |
|
$-36.04M |
|
$13.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.15 |
|
-- |
|
-- |
|
0.07 |
|
0.08 |
|
100.00% |
|
-82389.36% |
|
-82389.36% |
|
-- |
|
-74397.87% |
|
-74397.87% |
|
$-119.68M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-20.82% |
|
-16.49% |
|
-13.30% |
|
-15.28% |
|
$6.21 |
|
$-1.17 |
|
$-1.17 |
|